Home Up Feedback Contents Search Sell your Prod. Meet us News           

 
Home • Up

C038

 

Home

GENTAUR

+32 1658 9045

or

0032 (0)16 41 44 07

+32 1650 9045

info@gentaur.com

Av. de l' Armée 68

B-1040 Brussels

BELGIUM

France

tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 Paris

Italia

tel 02 36 00 65 93

fax 02 36 00 65 94

20135 Milano

Deutschland

tel +32 1658 9045

fax +32 1650 9045

Polska

Tel 058 710 33 44

Fax 00 32 16 50 90 45

ul. Grunwaldzka 88A/2

81-771 Sopot

日本

tel +81 78 386 0860

fax +81 78 306 0296

Minaatojimaminami-manchi

Chuo-ku, Kobe

065-0047

Österreich
+43720880899

Canada Montreal
+15149077481

Česká republika Praha
+420246019719

Danmark
+4569918806

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494

Magyarország Budapest
+3619980547

Ireland Dublin
+35316526556

Luxembourg
+35220880274

Nederland
+31208080893

Norge Oslo
+4721031366

Polska Warszawa
+48223988221

Sverige Stockholm
+46852503438

Schweiz Züri
+41435006251

US New York
+17185132983

Other Countries
0032 (0)16 41 44 07


 

 

 

 

 

Clonagen

Gentaur

Genprice

Bioxys

Labprice

Recombinant Human Vascular Endothelial Growth Inhibitor (VEGI-192)
(Cat. No.: C038)



Background:
    Vascular endothelial growth inhibitor (VEGI; TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.

Description:
    Recombinant human VEGI-192 produced in E. coli is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21858 Dalton.

Quality Control:
    Biological Activity: The ED50 as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells) is less then 5μg/ml.
    Purity: Greater than 95.0% as determined by:
        (a) Analysis by RP-HPLC.
        (b) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
    Amino-Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Gln-Leu-Thr-Lys.
    Endotoxin: Less than 0.1 ng/µg (1 IEU/µg) of rHuVEGI.

Formulation:
    The protein was lyophilized after extensive dialysis against 0.5M NaCl, 50mM Tris-HCl buffer, pH 7.5.

Storage:
    Lyophilized VEGI-192 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution VEGI-192 should be stored at 4°C between 2-7 days and for future use below -18°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

Reconstitution:
    It is recommended to reconstitute the lyophilized VEGI-192 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

 

 


 
*NOTE: ALL PRODUCTS ARE FOR RESEARCH USE ONLY

 

Send mail to webmaster@gentaur.com with questions or comments about this web site.
Copyright © 2002 GENTAUR Molecular Products
Last modified: 05/29/09